Law Firms Urge Nektar Investors to Seek Lead Role in Securities Suit Over REZOLVE-AA Trial

Overview

• Fresh notices from the Schall Law Firm and DJS Law Group highlight a filed class action targeting Nektar Therapeutics’ statements about its REZOLVE-AA trial.
• The complaint alleges patient enrollment failed to follow protocol standards for rezpegaldesleukin, which likely skewed results and overstated the trial’s integrity.
• The suit asserts violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5.
• Eligible investors are those who bought NKTR shares between February 26, 2025 and December 15, 2025, with a court deadline of May 5, 2026 to move for lead-plaintiff status.
• The case has not been certified as a class action, and multiple firms, including Rosen, are soliciting investors who are not represented unless they retain counsel.